Review article: Acute severe ulcerative colitis - Evidence-based consensus statements

Alimentary Pharmacology and Therapeutics

Volumn 44, Issue 2, 2016, Pages 127-144

  Chen, J H ^a   Andrews, J M ^b   Kariyawasam, V ^c   Moran, N ^a   Gounder, P ^a   Collins, G ^a   Walsh, A J ^d   Connor, S ^e   Lee, T W T ^f   Koh, C E ^g   Chang, J ^a   Paramsothy, S ^d   Tattersall, S ^h   Lemberg, D A ⁱ   Radford Smith, G ^j   Lawrance, I C ^k   McLachlan, A ^a   Moore, G T ^l   Corte, C ^a   Katelaris, P ^a   Leong, R W ^a   more..

^a ANZAC Research Institute   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c BLACKTOWN HOSPITAL   (Australia)

^d ST VINCENT S HOSPITAL   (Australia)

^e LIVERPOOL HOSPITAL   (Australia)

^f WOLLONGONG HOSPITAL   (Australia)

^g ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^h ROYAL NORTH SHORE HOSPITAL   (Australia)

ⁱ SYDNEY CHILDREN'S HOSPITAL   (Australia)

^j ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^k ST JOHN OF GOD HOSPITAL   (Australia)

^l MONASH MEDICAL CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALLOPURINOL; CYCLOSPORIN A; GOLIMUMAB; HYDROCORTISONE; INFLIXIMAB; MERCAPTOPURINE; TACROLIMUS; VEDOLIZUMAB; CYCLOSPORIN;

ACUTE DISEASE; ACUTE SEVERE ULCERATIVE COLITIS; ARTICLE; AUSTRALIA; CLINICAL PRACTICE; COLITIS; COLON RESECTION; CONSENSUS; CYTOMEGALOVIRUS COLITIS; DELPHI STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DRUG RESPONSE; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; HOSPITALIZATION; HUMAN; MAINTENANCE THERAPY; MORTALITY; PATIENT CARE; PATIENT MONITORING; PRIORITY JOURNAL; SIGMOIDOSCOPY; SYSTEMATIC REVIEW; THROMBOSIS PREVENTION; ULCERATIVE COLITIS; VENOUS THROMBOEMBOLISM; COLITIS, ULCERATIVE; PROCEDURES;

AUSTRALIA; COLECTOMY; COLITIS, ULCERATIVE; CONSENSUS; CYCLOSPORINE; HOSPITALIZATION; HUMANS; INFLIXIMAB; VENOUS THROMBOEMBOLISM;

EID: 84971434933     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13670     Document Type: Article

References (224)

1. Bernstein CN, Ng SC, Lakatos PL, Moum B, Loftus EV Jr,. A review of mortality and surgery in ulcerative colitis: milestones of the seriousness of the disease. Inflamm Bowel Dis 2013; 19: 2001-10.
2. Turner D, Walsh CM, Steinhart AH, Griffiths AM,. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-10.
3. Lynch RW, Lowe D, Protheroe A, Driscoll R, Rhodes JM, Arnott ID,. Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit. Aliment Pharmacol Ther 2013; 38: 935-45.
4. Bitton A, Buie D, Enns R, et al,. Treatment of hospitalized adult patients with severe ulcerative colitis: Toronto consensus statements. Am J Gastroenterol 2012; 107: 179-94; author reply 95.
5. Grimer M,. The CARI guidelines. Calcineurin inhibitors in renal transplantation: pregnancy, lactation and calcineurin inhibitors. Nephrology 2007; 12 (Suppl. 1): S98-105.
6. Fink A, Kosecoff J, Chassin M, Brook RH,. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984; 74: 979-83.
7. Dignass A, Lindsay JO, Sturm A, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012a; 6: 991-1030.
8. Kornbluth A, Sachar DB,. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85.
9. Brown SR, Haboubi N, Hampton J, George B, Travis SP,. The management of acute severe colitis: ACPGBI position statement. Colorectal Dis 2008; 10 (Suppl. 3): 8-29.
10. Dignass A, Eliakim R, Magro F, et al,. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012b; 6: 965-90.
11. Jakobovits SL, Travis SP,. Management of acute severe colitis. Br Med Bull 2005; 75-76: 131-44.
12. Truelove SC, Witts LJ,. Cortisone in ulcerative colitis: final report on a therapeutic trial. Br Med J 1955; 2: 1041-8.
13. Travis S, Dinesen L,. Remission in trials of ulcerative colitis: what does it mean? Pract Gastroenterol 2006; 30: 17-20.
14. Travis SP, Higgins PD, Orchard T, et al,. Review article: defining remission in ulcerative colitis. Aliment Pharmacol Ther 2011; 34: 113-24.
15. Colombel JF, Rutgeerts P, Reinisch W, et al,. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141: 1194-201.
16. Paoluzi OA, Iacopini F, Pica R, et al,. Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. Aliment Pharmacol Ther 2005; 21: 1111-9.
17. Dignass AU, Bokemeyer B, Adamek H, et al,. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. Clin Gastroenterol Hepatol 2009; 7: 762-9.
18. Bitton A, Peppercorn MA, Antonioli DA, et al,. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001; 120: 13-20.
19. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME,. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991; 32: 174-8.
20. Wright R, Truelove SR,. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1966; 11: 847-57.
21. Burger DC, Thomas SJ, Walsh AJ, et al,. Depth of remission may not predict outcome of UC over 2 years. Gut 2011; 60 (Suppl. 1): A133.
22. Rubin D, Huo D, Hetzel J, et al,. Increased degree of histological inflammation predicts colectomy and hospitalisation in patients with ulcerative colitis. Gastroenterology 2007; 132 (Suppl 1): A-19 (Abstract 103).
23. Nguyen GC, Kaplan GG, Harris ML, Brant SR,. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-50.
24. Rodemann JF, Dubberke ER, Reske KA, da Seo H, Stone CD,. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-44.
25. Issa M, Ananthakrishnan AN, Binion DG,. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis 2008; 14: 1432-42.
26. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
27. Travis SP, Schnell D, Krzeski P, et al,. Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut 2012; 61: 535-42.
28. Travis SP, Schnell D, Krzeski P, et al,. Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology 2013; 145: 987-95.
29. Corte CJ, Fernandopulle A, Catuneanu A, et al,. Association between the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and outcomes in acute severe ulcerative colitis. J Crohns Colitis 2015; 9: 376-81.
30. Rotter T, Kinsman L, James E, et al,. Clinical pathways: effects on professional practice, patient outcomes, length of stay and hospital costs. Cochrane Database Syst Rev 2010; 17: CD006632.
31. The UK IBD Audit Steering Group. UK IBD Audit 2nd Round Report. National Results for the Organisation & Process of Adult IBD Care in the UK, 2008. Generic Hospital Report. Royal College of Physicians, 2009.
32. The UK IBD Audit Steering Group. Report of the results for the national clinical audit of adult inflammatory bowel disease inpatient care in the UK. Round 3. National report. Royal College of Physicians. 2012.
33. Royal College of Physicians. National clinical audit report of inpatient care for people with ulcerative colitis: adult national report, 2014.
34. Travis SP, Farrant JM, Ricketts C, et al,. Predicting outcome in severe ulcerative colitis. Gut 1996; 38: 905-10.
35. Lindgren SC, Flood LM, Kilander AF, Lofberg R, Persson TB, Sjodahl RI,. Early predictors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 1998; 10: 831-5.
36. Ho GT, Mowat C, Goddard CJ, et al,. Predicting the outcome of severe ulcerative colitis: development of a novel risk score to aid early selection of patients for second-line medical therapy or surgery. Aliment Pharmacol Ther 2004; 19: 1079-87.
37. Turner D, Walsh CM, Benchimol EI, et al,. Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Gut 2008; 57: 331-8.
38. Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M,. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971-6.
39. Ulcerative colitis. Management in adults, children, and young people. NICE Clinical Guideline 166, 2013a.
40. Cassinotti A, Keshav S, Ardizzone S, et al,. IBD care in Europe: a comparative audit of the inpatient management of Crohn's disease and ulcerative colitis using the national UK IBD audit tool. J Crohns Colitis 2009; 3: 291-301.
41. Standards for the healthcare of people who have Inflammatory Bowel Disease (IBD): IBD standards-2013 update, 2014.
42. O'Connor M, Bager P, Duncan J, et al,. N-ECCO Consensus statements on the European nursing roles in caring for patients with Crohn's disease or ulcerative colitis. J Crohns Colitis 2013; 7: 744-64.
43. Eiden K,. Nutritional considerations in inflammatory bowel disease. Pract Gastroenterol 2003; 5: 33-54.
44. Gonzalez-Huix F, Fernandez-Banares F, Esteve-Comas M, et al,. Enteral versus parenteral nutrition as adjunct therapy in acute ulcerative colitis. Am J Gastroenterol 1993; 88: 227-32.
45. McIntyre PB, Powell-Tuck J, Wood SR, et al,. Controlled trial of bowel rest in the treatment of severe acute colitis. Gut 1986; 27: 481-5.
46. Grainge MJ, West J, Card TR,. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet 2010; 375: 657-63.
47. Kappelman MD, Horvath-Puho E, Sandler RS, et al,. Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut 2011; 60: 937-43.
48. Nguyen GC, Sam J,. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 2272-80.
49. Wang JY, Terdiman JP, Vittinghoff E, Minichiello T, Varma MG,. Hospitalized ulcerative colitis patients have an elevated risk of thromboembolic events. World J Gastroenterol 2009; 15: 927-35.
50. Saleh T, Matta F, Yaekoub AY, Danescu S, Stein PD,. Risk of venous thromboembolism with inflammatory bowel disease. Clin Appl Thromb Hemost 2011; 17: 254-8.
51. Kahn SR, Lim W, Dunn AS, et al,. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e195S-226S.
52. Truelove SC, Jewell DP,. Intensive intravenous regimen for severe attacks of ulcerative colitis. Lancet 1974; 1: 1067-70.
53. Lennard-Jones JE, Ritchie JK, Hilder W, Spicer CC,. Assessment of severity in colitis: a preliminary study. Gut 1975; 16: 579-84.
54. Jarnerot G, Hertervig E, Friis-Liby I, et al,. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
55. Lees CW, Heys D, Ho GT, et al,. A retrospective analysis of the efficacy and safety of infliximab as rescue therapy in acute severe ulcerative colitis. Aliment Pharmacol Ther 2007; 26: 411-9.
56. Regueiro M, Curtis J, Plevy S,. Infliximab for hospitalized patients with severe ulcerative colitis. J Clin Gastroenterol 2006; 40: 476-81.
57. Jakobovits SL, Jewell DP, Travis SP,. Infliximab for the treatment of ulcerative colitis: outcomes in Oxford from 2000 to 2006. Aliment Pharmacol Ther 2007; 25: 1055-60.
58. Halpin SJ, Hamlin PJ, Greer DP, Warren L, Ford AC,. Efficacy of infliximab in acute severe ulcerative colitis: a single-centre experience. World J Gastroenterol 2013; 19: 1091-7.
59. Lichtiger S, Present DH, Kornbluth A, et al,. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841-5.
60. van Assche G, D'Haens G, Noman M, et al,. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 1025-31.
61. Mocciaro F, Renna S, Orlando A, et al,. Cyclosporine or infliximab as rescue therapy in severe refractory ulcerative colitis: early and long-term data from a retrospective observational study. J Crohns Colitis 2012; 6: 681-6.
62. Croft A, Walsh A, Doecke J, Cooley R, Howlett M, Radford-Smith G,. Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab. Aliment Pharmacol Ther 2013; 38: 294-302.
63. Seagrove AC, Alam MF, Alrubaiy L, et al,. Randomised controlled trial. Comparison Of iNfliximab and ciclosporin in STeroid Resistant Ulcerative Colitis: Trial design and protocol (CONSTRUCT). BMJ Open 2014; 4: e005091.
64. Moskovitz DN, Van Assche G, Maenhout B, et al,. Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis. Clin Gastroenterol Hepatol 2006; 4: 760-5.
65. Reinisch W, Sandborn WJ, Hommes DW, et al,. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 780-7.
66. Feagan BG, Rutgeerts P, Sands BE, et al,. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med 2013; 369: 699-710.
67. Sandborn WJ, Feagan BG, Marano C, et al,. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2014; 146: 85-95; quiz e14-5.
68. Ogata H, Kato J, Hirai F, et al,. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm Bowel Dis 2012; 18: 803-8.
69. Ogata H, Matsui T, Nakamura M, et al,. A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006; 55: 1255-62.
70. Baumgart DC, Macdonald JK, Feagan B,. Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis. Cochrane Database Syst Rev 2008; 16: CD007216.
71. Hogenauer C, Wenzl HH, Hinterleitner TA, Petritsch W,. Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther 2003; 18: 415-23.
72. Schmidt KJ, Herrlinger KR, Emmrich J, et al,. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis-experience in 130 patients. Aliment Pharmacol Therap 2013; 37: 129-36.
73. Miyoshi J, Matsuoka K, Inoue N, et al,. Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. J Crohns Colitis 2013; 7: e609-14.
74. Randall J, Singh B, Warren BF, Travis SP, Mortensen NJ, George BD,. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg 2010; 97: 404-9.
75. Maser EA, Deconda D, Lichtiger S, Ullman T, Present DH, Kornbluth A,. Cyclosporine and infliximab as rescue therapy for each other in patients with steroid-refractory ulcerative colitis. Clin Gastroenterol Hepatol 2008; 6: 1112-6.
76. Manosa M, Lopez San Roman A, Garcia-Planella E, et al,. Infliximab rescue therapy after cyclosporin failure in steroid-refractory ulcerative colitis. Digestion 2009; 80: 30-5.
77. Herrlinger KR, Barthel DN, Schmidt KJ, et al,. Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. Aliment Pharmacol Ther 2010; 31: 1036-41.
78. Aceituno M, Garcia-Planella E, Heredia C, et al,. Steroid-refractory ulcerative colitis: predictive factors of response to cyclosporine and validation in an independent cohort. Inflamm Bowel Dis 2008; 14: 347-52.
79. Huaman Rios JW, Casellas Jorda F, Malagelada Benapres JR,. Predictive factors of poor response to intravenous cyclosporine in steroid-refractory ulcerative colitis. Rev Esp Enferm Dig 2009; 101: 163-71.
80. Oussalah A, Evesque L, Laharie D, et al,. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol 2010; 105: 2617-25.
81. Burns EM, Bottle A, Aylin P, et al,. Volume analysis of outcome following restorative proctocolectomy. Br J Surg 2011; 98: 408-17.
82. Nguyen GC, Steinhart AH,. The impact of surgeon volume on postoperative outcomes after surgery for Crohn's disease. Inflamm Bowel Dis 2014; 20: 301-6.
83. Karanicolas PJ, Dubois L, Colquhoun PH, Swallow CJ, Walter SD, Guyatt GH,. The more the better? The impact of surgeon and hospital volume on in-hospital mortality following colorectal resection. Ann Surg 2009; 249: 954-9.
84. Bass EM, Del Pino A, Tan A, Pearl RK, Orsay CP, Abcarian H,. Does preoperative stoma marking and education by the enterostomal therapist affect outcome? Dis Colon Rectum 1997; 40: 440-2.
85. Person B, Ifargan R, Lachter J, Duek SD, Kluger Y, Assalia A,. The impact of preoperative stoma site marking on the incidence of complications, quality of life, and patient's independence. Dis Colon Rectum 2012; 55: 783-7.
86. Ross H, Steele SR, Varma M, et al,. Practice parameters for the surgical treatment of ulcerative colitis. Dis Colon Rectum 2014; 57: 5-22.
87. Gu J, Stocchi L, Remzi FH, Kiran RP,. Total abdominal colectomy for severe ulcerative colitis: does the laparoscopic approach really have benefit? Surg Endosc 2014; 28: 617-25.
88. Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR,. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 49-54.
89. Brandse JF, der van Kleij D, Wolbink G-J, et al,. 786 the pharmacokinetics of infliximab induction therapy in patients with moderate to severe ulcerative colitis. Gastroenterology; 146: S-134.
90. Brandse JF, Wildenberg M, de Bruyn JR, et al,. 157 fecal loss of infliximab as a cause of lack of response in severe inflammatory bowel disease. Gastroenterology; 144: S-36.
91. Gibson DJ, Heetun ZS, Redmond CE, et al,. An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. Clin Gastroenterol Hepatol 2015; 13: 330-5 e1.
92. Mortimore M, Gibson PR, Selby WS, Radford-Smith GL, Florin TH,. Early Australian experience with infliximab, a chimeric antibody against tumour necrosis factor-alpha, in the treatment of Crohn's disease: is its efficacy augmented by steroid-sparing immunosuppressive therapy? The Infliximab User Group. Int Med J 2001; 31: 146-50.
93. Arnott ID, McNeill G, Satsangi J,. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment Pharmacol Ther 2003; 17: 1451-7.
94. Sokol H, Seksik P, Carrat F, et al,. Usefulness of co-treatment with immunomodulators in patients with inflammatory bowel disease treated with scheduled infliximab maintenance therapy. Gut 2010; 59: 1363-8.
95. Panaccione R, Ghosh S, Middleton S, et al,. Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology 2014; 146: 392-400.e3.
96. Lichtiger S, Present DH,. Preliminary report: cyclosporin in treatment of severe active ulcerative colitis. Lancet 1990; 336: 16-9.
97. Lichtiger S,. Cyclosporine therapy in inflammatory bowel disease: open-label experience. Mt Sinai J Med 1990; 57: 315-9.
98. D'Haens G, Lemmens L, Geboes K, et al,. Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001; 120: 1323-9.
99. Laharie D, Bourreille A, Branche J, et al,. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 1909-15.
100. Rethinking medicines decision-making in Australian hospitals: Guiding principles for the quality use of off-label medicines. Council of Australian Therapeutic Advisory Group, 2013b.
101. Chang J, Leong RW,. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opin Biol Ther 2014; 14: 27-36.
102. Alexander M, King J, Bajel A, et al,. Australian consensus guidelines for the safe handling of monoclonal antibodies for cancer treatment by healthcare personnel, 2014.
103. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK,. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012; 9: CD000478.
104. Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R,. 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 1227-33.
105. Sood A, Midha V, Sood N, Avasthi G,. Azathioprine versus sulfasalazine in maintenance of remission in severe ulcerative colitis. Indian J Gastroenterol 2003; 22: 79-81.
106. Sood A, Midha V, Sood N, Kaushal V,. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000; 19: 14-6.
107. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V,. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002; 37: 270-4.
108. Cheifetz AS, Stern J, Garud S, et al,. Cyclosporine is safe and effective in patients with severe ulcerative colitis. J Clin Gastroenterol 2011; 45: 107-12.
109. Bamba S, Tsujikawa T, Inatomi O, et al,. Factors affecting the efficacy of cyclosporin A therapy for refractory ulcerative colitis. J Gastroenterol Hepatol 2010; 25: 494-8.
110. Cohen RD, Stein R, Hanauer SB,. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 1587-92.
111. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X,. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 15-36.
112. Ansari A, Arenas M, Greenfield SM, et al,. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008a; 28: 973-83.
113. Colombel JF, Ferrari N, Debuysere H, et al,. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 1025-30.
114. Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE,. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 1081-5.
115. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI,. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 641-9.
116. Kirschner BS,. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998; 115: 813-21.
117. Gisbert JP, Gomollon F,. Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review. Am J Gastroenterol 2008; 103: 1783-800.
118. Bastida G, Nos P, Aguas M, et al,. Incidence, risk factors and clinical course of thiopurine-induced liver injury in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2005; 22: 775-82.
119. Gisbert JP, Luna M, Gonzalez-Lama Y, et al,. Liver injury in inflammatory bowel disease: long-term follow-up study of 786 patients. Inflamm Bowel Dis 2007; 13: 1106-14.
120. Hindorf U, Lindqvist M, Hildebrand H, Fagerberg U, Almer S,. Adverse events leading to modification of therapy in a large cohort of patients with inflammatory bowel disease. Aliment Pharmacol Ther 2006; 24: 331-42.
121. Bermejo F, Lopez-Sanroman A, Algaba A, et al,. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 120-4.
122. Vernier-Massouille G, Cosnes J, Lemann M, et al,. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut 2007; 56: 1404-9.
123. Seksik P, Mary JY, Beaugerie L, et al,. Incidence of nodular regenerative hyperplasia in inflammatory bowel disease patients treated with azathioprine. Inflamm Bowel Dis 2011; 17: 565-72.
124. Dubinsky MC, Lamothe S, Yang HY, et al,. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 705-13.
125. Cuffari C, Hunt S, Bayless T,. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 642-6.
126. Gupta P, Gokhale R, Kirschner BS,. 6-mercaptopurine metabolite levels in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 33: 450-4.
127. Wright S, Sanders DS, Lobo AJ, Lennard L,. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 1123-8.
128. Cuffari C, Theoret Y, Latour S, Seidman G,. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 401-6.
129. Osterman MT, Kundu R, Lichtenstein GR, Lewis JD,. Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006; 130: 1047-53.
130. Lowry PW, Franklin CL, Weaver AL, et al,. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 665-70.
131. Reinshagen M, Schutz E, Armstrong VW, et al,. 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial. Clin Chem 2007; 53: 1306-14.
132. Gonzalez-Lama Y, Bermejo F, Lopez-Sanroman A, et al,. Thiopurine methyl-transferase activity and azathioprine metabolite concentrations do not predict clinical outcome in thiopurine-treated inflammatory bowel disease patients. Aliment Pharmacol Ther 2011; 34: 544-54.
133. Ihekweazu FD, Kellermayer R,. Allopurinol: a useful adjunct to thiopurine therapy for pediatric ulcerative colitis in the biologic era. J Pediatr Gastroenterol Nutr 2014; 59: 22-4.
134. Min MX, Weinberg DI, McCabe RP,. Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use. J Clin Pharm Ther 2014; 39: 107-11.
135. Seinen ML, van Asseldonk DP, de Boer NK, et al,. The effect of allopurinol and low-dose thiopurine combination therapy on the activity of three pivotal thiopurine metabolizing enzymes: results from a prospective pharmacological study. J Crohns Colitis 2013; 7: 812-9.
136. Hoentjen F, Seinen ML, Hanauer SB, et al,. Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 363-9.
137. Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD,. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis 2012; 6: 905-12.
138. Gerich ME, Quiros JA, Marcin JP, Tennyson L, Henthorn M, Prindiville TP,. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine. J Crohns Colitis 2010; 4: 546-52.
139. Ansari A, Patel N, Sanderson J, O'Donohue J, Duley JA, Florin TH,. Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2010; 31: 640-7.
140. Leung Y, Sparrow MP, Schwartz M, Hanauer SB,. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J Crohns Colitis 2009; 3: 162-7.
141. Ansari A, Elliott T, Baburajan B, et al,. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008b; 28: 734-41.
142. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB,. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin Gastroenterol Hepatol 2007; 5: 209-14.
143. Subhani JM, Hamiliton MI,. Review article: the management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther 1998; 12: 1039-53.
144. Mahadevan U, Sandborn WJ, Li DK, Hakimian S, Kane S, Corley DA,. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106-12.
145. Lin HC, Chiu CC, Chen SF, Lou HY, Chiu WT, Chen YH,. Ulcerative colitis and pregnancy outcomes in an Asian population. Am J Gastroenterol 2010; 105: 387-94.
146. Stephansson O, Larsson H, Pedersen L, et al,. Congenital abnormalities and other birth outcomes in children born to women with ulcerative colitis in Denmark and Sweden. Inflamm Bowel Dis 2011; 17: 795-801.
147. Dejaco C, Angelberger S, Waldhoer T, Haas T, Wenzl H, Knoflach P,. 220 risk factors for pregnancy outcome in patients with inflammatory bowel disease (IBD). Gastroenterology 2006; 130 (Suppl 2): A-39.
148. Habal FM, Huang VW,. Review article: a decision-making algorithm for the management of pregnancy in the inflammatory bowel disease patient. Aliment Pharmacol Ther 2012; 35: 501-15.
149. Carmichael SL, Shaw GM,. Maternal corticosteroid use and risk of selected congenital anomalies. Am J Med Genet 1999; 86: 242-4.
150. Pradat P, Robert-Gnansia E, Di Tanna GL, Rosano A, Lisi A, Mastroiacovo P,. First trimester exposure to corticosteroids and oral clefts. Birth Defects Res A Clin Mol Teratol 2003; 67: 968-70.
151. Carmichael SL, Shaw GM, Ma C, Werler MM, Rasmussen SA, Lammer EJ,. Maternal corticosteroid use and orofacial clefts. Am J Obstet Gynecol 2007; 197: 585.e1-7; discussion 683-4, e1-7.
152. Park-Wyllie L, Mazzotta P, Pastuszak A, et al,. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology 2000; 62: 385-92.
153. Bush MC, Patel S, Lapinski RH, Stone JL,. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004; 15: 237-41.
154. Gur C, Diav-Citrin O, Shechtman S, Arnon J, Ornoy A,. Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study. Reprod Toxicol 2004; 18: 93-101.
155. Hviid A, Molgaard-Nielsen D,. Corticosteroid use during pregnancy and risk of orofacial clefts. CMAJ 2011; 183: 796-804.
156. Mogadam M, Dobbins WO 3rd, Korelitz BI, Ahmed SW,. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology 1981; 80: 72-6.
157. Skuladottir H, Wilcox AJ, Ma C, et al,. Corticosteroid use and risk of orofacial clefts. Birth Defects Res A Clin Mol Teratol 2014; 100: 499-506.
158. van der Woude CJ, Kolacek S, Dotan I, et al,. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010; 4: 493-510.
159. Goldstein LH, Dolinsky G, Greenberg R, et al,. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Res A Clin Mol Teratol 2007; 79: 696-701.
160. Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT,. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther 2007; 25: 73-81.
161. Norgard B, Pedersen L, Christensen LA, Sorensen HT,. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish nationwide cohort study. Am J Gastroenterol 2007; 102: 1406-13.
162. Cleary BJ, Kallen B,. Early pregnancy azathioprine use and pregnancy outcomes. Birth Defects Res A Clin Mol Teratol 2009; 85: 647-54.
163. Francella A, Dyan A, Bodian C, Rubin P, Chapman M, Present DH,. The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003; 124: 9-17.
164. Shim L, Eslick GD, Simring AA, Murray H, Weltman MD,. The effects of azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011; 5: 234-8.
165. Coelho J, Beaugerie L, Colombel JF, et al,. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 2011; 60: 198-203.
166. Jharap B, de Boer NK, Stokkers P, et al,. Intrauterine exposure and pharmacology of conventional thiopurine therapy in pregnant patients with inflammatory bowel disease. Gut 2014; 63: 451-7.
167. van der Woude CJ, Ardizzone S, Bengtson MB, et al,. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis 2015; 9: 107-24.
168. Hendy P, Chadwick G, Hart A,. Republished curriculum based clinical review: IBD: reproductive health, pregnancy and lactation. Postgrad Med J 1074; 2015: 230-5.
169. Paziana K, del Monaco M, Cardonick E, et al,. Ciclosporin use during pregnancy. Drug Saf 2013; 36: 279-94.
170. Bar Oz B, Hackman R, Einarson T, Koren G,. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001; 71: 1051-5.
171. Moretti ME, Sgro M, Johnson DW, et al,. Cyclosporine excretion into breast milk. Transplantation 2003; 75: 2144-6.
172. Thiru Y, Bateman DN, Coulthard MG,. Successful breast feeding while mother was taking cyclosporin. BMJ 1997; 315: 463.
173. Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I,. Breast-feeding during treatment with cyclosporine. Transplantation 1998; 65: 253-5.
174. Munoz-Flores-Thiagarajan KD, Easterling T, Davis C, Bond EF,. Breast-feeding by a cyclosporine-treated mother. Obstet Gynecol 2001; 97: 816-8.
175. Osadchy A, Koren G,. Cyclosporine and lactation: when the mother is willing to breastfeed. Ther Drug Monit 2011; 33: 147-8.
176. Armenti VT, Radomski JS, Moritz MJ, Gaughan WJ, McGrory CH, Coscia LA,. Report from the National Transplantation Pregnancy Registry (NTPR): outcomes of pregnancy after transplantation. Clin Transpl 2003; 131-41.
177. Lichtenstein GR, Feagan BG, Cohen RD, et al,. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-30.
178. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR,. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
179. Mahadevan U, Martin CF, Sandler RS, et al,. 865 PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012; 142 (Suppl 1): S-149
180. Julsgaard M, Christensen LA, Lawrence I, Gearry R, Connell W, Grosen A,. P377. Pregnancy outcome and counselling of anti-TNF-alpha treated IBD women: an ongoing international multicentre study. J Crohns Colitis 2014; 8 (Suppl 1): S222-3.
181. Mahadevan U, Martin CF, Dubinsky M, Kane SV, Sands BE, Sandborn W,. 960 exposure to anti-TNFa therapy in the third trimester of pregnancy is not associated with increased adverse outcomes: results from the PIANO registry. Gastroenterology 2014; 146 (Suppl 1): S-170.
182. Julsgaard M, Christensen LA, Gibson PR, et al,. Concentrations of Adalimumab and Infliximab in Mothers and Newborns, and Effects on Infection. Gastroenterology 2016; doi: 10.1053/j.gastro.2016.04.002. [Epub ahead of print].
183. Mahadevan U, Cucchiara S, Hyams JS, et al,. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: pregnancy and pediatrics. Am J Gastroenterol 2011; 106: 214-23; quiz 24.
184. Rahier JF, Magro F, Abreu C, et al,. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2014; 8: 443-68.
185. Smith MB, Hanauer SB,. Pneumocystis carinii pneumonia during cyclosporine therapy for ulcerative colitis. N Engl J Med 1992; 327: 497-8.
186. Scott AM, Myers GA, Harms BA,. Pneumocystis carinii pneumonia postrestorative proctocolectomy for ulcerative colitis: a role for perioperative prophylaxis in the cyclosporine era? Report of a case and review of the literature. Dis Colon Rectum 1997; 40: 973-6.
187. Quan VA, Saunders BP, Hicks BH, Sladen GE,. Cyclosporin treatment for ulcerative colitis complicated by fatal Pneumocystis carinii pneumonia. BMJ 1997; 314: 363-4.
188. Takenaka R, Okada H, Mizuno M, et al,. Pneumocystis carinii pneumonia in patients with ulcerative colitis. J Gastroenterol 2004; 39: 1114-5.
189. Bernstein CN, Kolodny M, Block E, Shanahan F,. Pneumocystis carinii pneumonia in patients with ulcerative colitis treated with corticosteroids. Am J Gastroenterol 1993; 88: 574-7.
190. Long MD, Farraye FA, Okafor PN, Martin C, Sandler RS, Kappelman MD,. Increased risk of pneumocystis jiroveci pneumonia among patients with inflammatory bowel disease. Inflamm Bowel Dis 2013; 19: 1018-24.
191. Mansharamani NG, Garland R, Delaney D, Koziel H,. Management and outcome patterns for adult Pneumocystis carinii pneumonia, 1985 to 1995: comparison of HIV-associated cases to other immunocompromised states. Chest 2000; 118: 704-11.
192. Green H, Paul M, Vidal L, Leibovici L,. Prophylaxis of pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007; 82: 1052-9.
193. Ioannidis JP, Cappelleri JC, Skolnik PR, Lau J, Sacks HS,. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Arch Intern Med 1996; 156: 177-88.
194. Bucher HC, Griffith L, Guyatt GH, Opravil M,. Meta-analysis of prophylactic treatments against Pneumocystis carinii pneumonia and toxoplasma encephalitis in HIV-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 15: 104-14.
195. Kambham N, Vij R, Cartwright CA, Longacre T,. Cytomegalovirus infection in steroid-refractory ulcerative colitis: a case-control study. Am J Surg Pathol 2004; 28: 365-73.
196. Domenech E, Vega R, Ojanguren I, et al,. Cytomegalovirus infection in ulcerative colitis: a prospective, comparative study on prevalence and diagnostic strategy. Inflamm Bowel Dis 2008; 14: 1373-9.
197. Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A,. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm Bowel Dis 2006; 12: 879-84.
198. Matsuoka K, Iwao Y, Mori T, et al,. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol 2007; 102: 331-7.
199. Hommes DW, Sterringa G, van Deventer SJ, Tytgat GN, Weel J,. The pathogenicity of cytomegalovirus in inflammatory bowel disease: a systematic review and evidence-based recommendations for future research. Inflamm Bowel Dis 2004; 10: 245-50.
200. Nakase H, Chiba T,. TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience. Inflamm Bowel Dis 2010; 16: 550-1.
201. Criscuoli V, Mocciaro F, Orlando A, Rizzuto MR, Renda MC, Cottone M,. Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis. Inflamm Bowel Dis 2009; 15: 810-1.
202. Criscuoli V, Casa A, Orlando A, et al,. Severe acute colitis associated with CMV: a prevalence study. Dig Liver Dis 2004; 36: 818-20.
203. Minami M, Ohta M, Ohkura T, et al,. Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan. World J Gastroenterol 2007; 13: 754-60.
204. Kishore J, Ghoshal U, Ghoshal UC, et al,. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004; 53: 1155-60.
205. Papadakis KA, Tung JK, Binder SW, et al,. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 2137-42.
206. Lawlor G, Moss AC,. Cytomegalovirus in inflammatory bowel disease: pathogen or innocent bystander? Inflamm Bowel Dis 2010; 16: 1620-7.
207. Kandiel A, Lashner B,. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2857-65.
208. Boivin G, Handfield J, Toma E, et al,. Evaluation of the AMPLICOR cytomegalovirus test with specimens from human immunodeficiency virus-infected subjects. J Clin Microbiol 1998; 36: 2509-13.
209. Michaelides A, Liolios L, Glare EM, et al,. Increased human cytomegalovirus (HCMV) DNA load in peripheral blood leukocytes after lung transplantation correlates with HCMV pneumonitis. Transplantation 2001; 72: 141-7.
210. Kim YS, Kim YH, Kim JS, et al,. The prevalence and efficacy of ganciclovir on steroid-refractory ulcerative colitis with cytomegalovirus infection: a prospective multicenter study. J Clin Gastroenterol 2012; 46: 51-6.
211. Cottone M, Pietrosi G, Martorana G, et al,. Prevalence of cytomegalovirus infection in severe refractory ulcerative and Crohn's colitis. Am J Gastroenterol 2001; 96: 773-5.
212. de Jong MD, Galasso GJ, Gazzard B, et al,. Summary of the II international symposium on cytomegalovirus. Antiviral Res 1998; 39: 141-62.
213. Wilson MZ, Connelly TM, Tinsley A, Hollenbeak CS, Koltun WA, Messaris E,. Ulcerative colitis is associated with an increased risk of venous thromboembolism in the postoperative period: the results of a matched cohort analysis. Ann Surg 2015; 261: 1160-6.
214. Sharma A, Chatterjee S, Lichstein E, Mukherjee D,. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost 2012; 10: 2053-60.
215. Paul S, Del Tedesco E, Marotte H, et al,. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis 2013; 19: 2568-76.
216. Arias M, van de Casteele D, Drobne M, Ferrante I, Cleynen V, Ballet P,. Importance of trough levels and antibodies on the long-term efficacy of infliximab therapy in ulcerative colitis. J Crohns Colitis 2012; 6 (Suppl1): S5.
217. Pariente B, Pineton de Chambrun G, Krzysiek R, et al,. Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 1199-206.
218. Afif W, Loftus EV Jr, Faubion WA, et al,. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
219. Subramaniam K, D'Rozario J, Pavli P,. Lymphoma and other lymphoproliferative disorders in inflammatory bowel disease: a review. J Gastroenterol Hepatol 2013; 28: 24-30.
220. Beaugerie L, Brousse N, Bouvier AM, et al,. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25.
221. Biank VF, Sheth MK, Talano J, et al,. Association of Crohn's disease, thiopurines, and primary Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis. J Pediatr 2011; 159: 808-12.
222. Sokol H, Beaugerie L, Maynadie M, et al,. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2063-71.
223. Vos AC, Bakkal N, Minnee RC, et al,. Risk of malignant lymphoma in patients with inflammatory bowel diseases: a Dutch nationwide study. Inflamm Bowel Dis 2011; 17: 1837-45.
224. Siegel CA, Marden SM, Persing SM, Larson RJ, Sands BE,. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol 2009; 7: 874-81.